PL2523653T3 - Sposób wytwarzania kompozycji farmaceutycznych do przedłużonego uwalniania analogów somatostatyny - Google Patents

Sposób wytwarzania kompozycji farmaceutycznych do przedłużonego uwalniania analogów somatostatyny

Info

Publication number
PL2523653T3
PL2523653T3 PL11701938T PL11701938T PL2523653T3 PL 2523653 T3 PL2523653 T3 PL 2523653T3 PL 11701938 T PL11701938 T PL 11701938T PL 11701938 T PL11701938 T PL 11701938T PL 2523653 T3 PL2523653 T3 PL 2523653T3
Authority
PL
Poland
Prior art keywords
preparation
pharmaceutical compositions
sustained release
somatostatin analogs
somatostatin
Prior art date
Application number
PL11701938T
Other languages
English (en)
Inventor
Martin Montes
Thomas Ciaran Loughman
Chantal Roume
Roland Cherif-Cheikh
Original Assignee
Ipsen Pharma S.A.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma S.A.S. filed Critical Ipsen Pharma S.A.S.
Publication of PL2523653T3 publication Critical patent/PL2523653T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/31Somatostatins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
PL11701938T 2010-01-13 2011-01-11 Sposób wytwarzania kompozycji farmaceutycznych do przedłużonego uwalniania analogów somatostatyny PL2523653T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29464410P 2010-01-13 2010-01-13
PCT/EP2011/000069 WO2011085957A2 (en) 2010-01-13 2011-01-11 Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogs
EP11701938.0A EP2523653B1 (en) 2010-01-13 2011-01-11 Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogs

Publications (1)

Publication Number Publication Date
PL2523653T3 true PL2523653T3 (pl) 2018-09-28

Family

ID=43743499

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11701938T PL2523653T3 (pl) 2010-01-13 2011-01-11 Sposób wytwarzania kompozycji farmaceutycznych do przedłużonego uwalniania analogów somatostatyny

Country Status (25)

Country Link
US (3) US9352012B2 (pl)
EP (2) EP2523653B1 (pl)
JP (1) JP6029472B2 (pl)
KR (1) KR101915820B1 (pl)
CN (2) CN102711728B (pl)
AR (1) AR079896A1 (pl)
AU (1) AU2011206728B2 (pl)
BR (1) BR112012017435A2 (pl)
CA (1) CA2786181C (pl)
DK (1) DK2523653T3 (pl)
EA (1) EA023128B1 (pl)
ES (1) ES2677012T3 (pl)
HK (1) HK1222807A1 (pl)
HU (1) HUE038200T2 (pl)
IL (2) IL220538A (pl)
MX (1) MX343112B (pl)
NZ (1) NZ600891A (pl)
PL (1) PL2523653T3 (pl)
PT (1) PT2523653T (pl)
SG (1) SG182548A1 (pl)
TR (1) TR201809874T4 (pl)
TW (2) TW201600108A (pl)
UA (1) UA108872C2 (pl)
WO (1) WO2011085957A2 (pl)
ZA (1) ZA201205160B (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA023128B1 (ru) 2010-01-13 2016-04-29 Ипсен Фарма С.А.С. Способ получения инъекционной фармацевтической композиции с замедленным высвобождением ланреотида
EP2823808A1 (en) * 2013-07-09 2015-01-14 Ipsen Pharma S.A.S. Pharmaceutical composition for a sustained release of lanreotide
TW201605488A (zh) 2013-10-15 2016-02-16 大塚製藥股份有限公司 用以預防及/或治療多囊腎病之藥物
WO2015061503A1 (en) 2013-10-22 2015-04-30 Prolynx Llc Conjugates of somatostatin and its analogs
FR3079421A1 (fr) 2018-03-28 2019-10-04 Edix Sa Presentations injectables, seringues et compositions a liberation prolongee et/ou controlee de lanreotide
GR1009814B (el) * 2019-07-29 2020-09-11 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει ενα πεπτιδιο αναλογο σωματοστατινης
RU2742196C1 (ru) * 2019-09-11 2021-02-03 Общество с ограниченной ответственностью "Медицинские нанотехнологии" Фармацевтическая композиция для приготовления инъекционного раствора при использовании в лечении магнитной гипертермии и способ ее получения
CN112791177B (zh) * 2019-10-28 2023-06-20 深圳翰宇药业股份有限公司 注射用生长抑素冻干组合物及其制备方法
EP4192427A1 (en) 2020-08-07 2023-06-14 Pharmathen S.A. Process and apparatus for preparing viscous pharmaceutical formulations
LU101974B1 (en) 2020-08-07 2022-02-07 Pharmathen Sa Process and apparatus for preparing viscous pharmaceutical formulations
GR1010059B (el) * 2020-08-10 2021-08-13 Φαρματεν Α.Β.Ε.Ε. Διαδικασια και συσκευη για την παρασκευη παχυρευστων φαρμακοτεχνικων μορφων

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH085913B2 (ja) 1985-09-12 1996-01-24 ザ・アドミニストレ−タ−ズ・オブ・ザ・ツ−レイン・エデユケイシヨナル・フアンド 治療用ソマトスタチン同族体
SK15096A3 (en) 1993-08-09 1996-07-03 Biomeasure Inc Therapeutic peptide derivatives and a method of their application
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
FR2762319A1 (fr) * 1997-04-18 1998-10-23 Pharma Biotech Microcapsules presentant une liberation prolongee et leur procede de preparation
FR2776520B1 (fr) 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
US6506534B1 (en) * 1999-09-02 2003-01-14 Fujitsu Limited Negative resist composition, method for the formation of resist patterns and process for the production of electronic devices
IT1318539B1 (it) 2000-05-26 2003-08-27 Italfarmaco Spa Composizioni farmaceutiche a rilascio prolungato per lasomministrazione parenterale di sostanze idrofile biologicamente
US7098305B2 (en) 2001-09-06 2006-08-29 Ardana Bioscience Limited Sustained release of microcrystalline peptide suspensions
RS20050247A (en) 2002-09-27 2007-06-04 Zentaris Gmbh., Administration form for pharmaceutically active peptides with sustained release and method for the production thereof
CN1415378A (zh) * 2002-10-22 2003-05-07 南京长澳医药科技有限公司 生长抑素冻干粉针及其制备工艺
US6953447B2 (en) 2002-10-22 2005-10-11 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S) Pre-filled safety injection device with integrated waste collector
GB0428151D0 (en) 2004-12-22 2005-01-26 Novartis Ag Organic compounds
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
JP2010539045A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 治療剤としてのフィブロネクチン断片(196−203)の使用
US20090181068A1 (en) 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
CN102119022B (zh) 2008-08-12 2015-09-09 诺华股份有限公司 药物组合物
EP2168983A1 (fr) 2008-09-30 2010-03-31 Ipsen Pharma Nouveaux composés octapeptidiques et leur utilisation thérapeutique
US20110250243A1 (en) 2008-12-15 2011-10-13 Thomas Kissel Nanoparticle compositions
EA023128B1 (ru) 2010-01-13 2016-04-29 Ипсен Фарма С.А.С. Способ получения инъекционной фармацевтической композиции с замедленным высвобождением ланреотида

Also Published As

Publication number Publication date
US10206968B2 (en) 2019-02-19
KR20120125576A (ko) 2012-11-15
EP3378468A1 (en) 2018-09-26
SG182548A1 (en) 2012-08-30
US20130079282A1 (en) 2013-03-28
BR112012017435A2 (pt) 2020-08-25
EA201290637A1 (ru) 2013-01-30
CN102711728B (zh) 2016-01-20
CN102711728A (zh) 2012-10-03
CA2786181C (en) 2017-12-12
TR201809874T4 (tr) 2018-07-23
AU2011206728B2 (en) 2016-02-04
IL248510A0 (en) 2016-12-29
EP2523653B1 (en) 2018-04-11
ZA201205160B (en) 2013-03-27
CN105456206A (zh) 2016-04-06
IL220538A (en) 2016-12-29
EP2523653A2 (en) 2012-11-21
JP2013517228A (ja) 2013-05-16
CA2786181A1 (en) 2011-07-21
HUE038200T2 (hu) 2018-09-28
NZ600891A (en) 2014-05-30
UA108872C2 (uk) 2015-06-25
PT2523653T (pt) 2018-06-28
HK1222807A1 (zh) 2017-07-14
DK2523653T3 (en) 2018-07-16
MX2012007802A (es) 2012-08-31
WO2011085957A2 (en) 2011-07-21
AU2011206728A1 (en) 2012-08-30
TW201129371A (en) 2011-09-01
AR079896A1 (es) 2012-02-29
US9352012B2 (en) 2016-05-31
EA023128B1 (ru) 2016-04-29
ES2677012T3 (es) 2018-07-27
IL220538A0 (en) 2012-08-30
WO2011085957A3 (en) 2012-05-03
MX343112B (es) 2016-10-25
US20190167754A1 (en) 2019-06-06
TW201600108A (zh) 2016-01-01
CN105456206B (zh) 2018-12-14
KR101915820B1 (ko) 2018-11-06
TWI536999B (zh) 2016-06-11
JP6029472B2 (ja) 2016-11-24
US20160339075A1 (en) 2016-11-24

Similar Documents

Publication Publication Date Title
IL248510A0 (en) A process for preparing sustained release pharmaceutical preparations of somatostatin analogs
ZA201208336B (en) Controlled release pharmaceutical compositions of tapentadol
IL222199A0 (en) Process for preparation of dopo-derived compounds and compositions thereof
IL231414B (en) Preparations for the preparation of imaging agents
IL223535A (en) Solid medicinal compositions
ZA201206254B (en) Novel salts for the manufacture of pharmaceutical compositions
EP2609064A4 (en) PHARMACEUTICAL COMPOSITIONS WITH POH DERIVATIVES
ZA201103820B (en) Process for the preparation of tenofovir
EP2661273A4 (en) IRON PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION
EP2629786A4 (en) COMPOSITIONS FOR THE ADMINISTRATION OF MEDICAMENTS
PL2554168T3 (pl) Kompozycja farmaceutyczna do kontrolowanego uwalniania
HK1198466A1 (en) Prasugrel-containing immediate release stable oral pharmaceutical compositions
EP2523654A4 (en) IMMEDIATE RELEASE COMPOSITIONS OF MEDICAMENTS LABILES ACIDES
EP2540317A4 (en) SOLID PREPARATION WITH DELAYED RELEASE FOR ORAL ADMINISTRATION
EP2540318A4 (en) SOLID PREPARATION WITH DELAYED RELEASE FOR ORAL ADMINISTRATION
AP2012006645A0 (en) Pharmaceutical compositions comprising paracetamoland process for preparing the same
EP2780001A4 (en) SOLID ORAL ENTECAVIR COMPOSITIONS WITH FAST RELEASE
EP2405754A4 (en) PHARMACEUTICAL BUPRENORPHINE COMPOSITIONS WITH MODIFIED RELEASE
HK1188959A1 (zh) 磷霉素藥物組合物
HK1171020A1 (en) Process for preparation of pyrimidinylpyrazole compounds
EP2543373A4 (en) PHARMACEUTICAL COMPOSITION OF LEVOAMLODIPINE COMPOUND
EP2537851A4 (en) PROCESS FOR PREPARING B-GLYCOSIDE COMPOUNDS
ZA201205978B (en) Solid pharmaceutical composition for buccal administration of agomelatine
GB201407689D0 (en) Pharmaceutical compositions of antihypertensives
HUP1000624A2 (en) Novel salts suitable for the preparation of pharmaceutical compositions